Halozyme Therapeutics Stock Analysis (NASDAQ:HALO)

Add to My Stocks
$13.53 $0.07 (0.52%) HALO stock closing price Mar 24, 2017 (Closing)
Watch Robo Advisor Video of HALO Stock Analysis
Halozyme Therapeutics
Updated on : Mar 24, 2017
previous close
HALO 13.5 (0%)
S&P 500 2344 (0%)
Closing Price On: Mar 24, 2017
stock rating
RATING: ★★★★★★★★★★ (0/5)
Industry :
Medical-Biomed-Genetics
Sector :
Medical
5 Quarter Revenue
Revenue Growth
2016-Q4
$million
%
YOY GROWTH
Compared to the industry
Long Term Growth
5 Year CAGR:
21.2%
Operating Profit
Operating Margin:
-56.7%
Sector Average:
-6.4%
5 Quarter Net Profit
Net Margins
2016-Q4
%
LTM Margin
Cash Flow
Operating cash flow:
-$15.8M
Net Income:
-$27.4M
PROS      CONS
Long Term Growth
Operating Margins
Net Margins
ROE
FCF Margin
PE Valuation
PS Valuation
Rating: ★★★★★★★★★★ (0/5)
Relative Valuation
PE: N/A
HALO PS :
11.8
Industry PS :
4.7
Sector:   Medical.   *PE adjusted for one time items.
Other Metrics
Return on Equity:
-1359%
Free Cash Flow Margin:
-41.6%
Double Tap To Exit Full Screen
0:00
/

Halozyme Therapeutics Analysis Video

100 5 2

View Halozyme Therapeutics stock analysis video. This is our HALO analyst opinion covering the buy and sell arguments for HALO stock.

Halozyme Therapeutics, Inc. Stock Rating (2.1/5)

Our Halozyme Therapeutics stock opinion is based on fundamentals of the company. This Halozyme Therapeutics stock analysis is based on latest Q4 earnings for 2016. The stock price analysis takes into account a company's valuation metrics.

Should you buy HALO stock?

  • The company saw a significant growth in revenue with a 5 year CAGR of 21.2%.

Should you sell HALO stock?

  • Over the last twelve months, Halozyme Therapeutics posted an average operating loss margin of -56.7%.
  • Halozyme Therapeutics posted an average Net loss of -70.2% in the last twelve months.
  • The company does not have profits. Hence the PE ratio is meaningless for HALO stock.
  • The company is trading at a price to sales multiple of 11.8, which is overvalued in comparison to the Medical-Biomed-Genetics industry average multiple of 4.7.
  • A negative ROE of -1359% indicates that the company is not able to generate profits with the money shareholders have invested.
  • Halozyme Therapeutics has a negative FCF (Free Cash Flow) margin of -41.6%.

Comments on this video and Halozyme Therapeutics stock